Thomas Harding

Investment Stage

Focus Areas

About Investor

Thomas Harding is a Partner at Bridford Group, a private equity investor focused on founder-led businesses with long-term growth potential and a concern for societal or environmental welfare, investing in biotech, consumer health, education, wellness, impact-driven ventures, entertainment & sports, and climate/clean tech, with checks between $100K and $5M from seed through Series B. He serves as a Non-Executive Director at Touchlight Genetics, a DNA-based biotech company backed by Bridford Group, and holds director positions at several other Bridford portfolio companies including LenioBio, Grabyo, Penfold Technology, and Hudson River Biotechnology. Before Bridford Group, he worked on TMT investments at Access Industries and began his career in the private equity department at Weil, Gotshal & Manges. He holds an MA from the University of Cambridge and studied law at City University and finance at London Business School. He is based in London, England.